Urogen Pharma Stock Performance
| URGN Stock | USD 9.51 0.23 2.36% |
The entity has a beta of 1.42, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, UroGen Pharma will likely underperform. At this point, UroGen Pharma has a negative expected return of -0.46%. Please make sure to validate UroGen Pharma's treynor ratio, kurtosis, as well as the relationship between the Kurtosis and day typical price , to decide if UroGen Pharma performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days UroGen Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's technical and fundamental indicators remain very healthy which may send shares a bit higher in March 2025. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
Actual Historical Performance (%)
One Day Return (2.36) | Five Day Return (12.19) | Year To Date Return (11.12) | Ten Year Return (31.97) | All Time Return (31.97) |
1 | Wall Street Analysts Believe Urogen Pharma Could Rally 209.92 percent Heres is How to Trade | 12/02/2024 |
2 | UroGen Pharma Reveals Promising Developments in Latest 8-K Filing | 01/15/2025 |
3 | New Real-World Durability of Response Data for JELMYTO Reports 68 percent Recurrence-Free Survival Rate at Three Years Across a Broad Patient Population with Lo... | 01/22/2025 |
4 | Acquisition by Degnan Chris of 13450 shares of UroGen Pharma subject to Rule 16b-3 | 01/29/2025 |
5 | Acquisition by Elizabeth Barrett of 96377 shares of UroGen Pharma subject to Rule 16b-3 | 01/31/2025 |
6 | Disposition of 6667 shares by Jason Smith of UroGen Pharma subject to Rule 16b-3 | 02/04/2025 |
7 | Urogen Pharmas general counsel sells 82,202 in shares - MSN | 02/10/2025 |
8 | UroGen Announces Results from Subgroup Analyses of the Pivotal ENVISION Trial Evaluating Impact of Baseline Tumor Burden and Focality on Response to UGN-102 | 02/14/2025 |
9 | UroGen Advances Long-Term Growth Strategy by Acquiring a Next-Generation Investigational Oncolytic Virus and Announces Multiple Strategic Research Collaboration... | 02/20/2025 |
10 | Acquisition by Dong Kim of 12000 shares of UroGen Pharma subject to Rule 16b-3 | 02/21/2025 |
11 | Is UroGen Pharma Ltd. the Best Small-Cap Growth Stock to Buy Now | 02/25/2025 |
| Begin Period Cash Flow | 56.2 M |
UroGen |
UroGen Pharma Relative Risk vs. Return Landscape
If you would invest 1,270 in UroGen Pharma on November 28, 2024 and sell it today you would lose (319.00) from holding UroGen Pharma or give up 25.12% of portfolio value over 90 days. UroGen Pharma is currently does not generate positive expected returns and assumes 2.5921% risk (volatility on return distribution) over the 90 days horizon. In different words, 23% of stocks are less volatile than UroGen, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
UroGen Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for UroGen Pharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as UroGen Pharma, and traders can use it to determine the average amount a UroGen Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.179
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | URGN |
Estimated Market Risk
| 2.59 actual daily | 23 77% of assets are more volatile |
Expected Return
| -0.46 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.18 actual daily | 0 Most of other assets perform better |
Based on monthly moving average UroGen Pharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of UroGen Pharma by adding UroGen Pharma to a well-diversified portfolio.
UroGen Pharma Fundamentals Growth
UroGen Stock prices reflect investors' perceptions of the future prospects and financial health of UroGen Pharma, and UroGen Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on UroGen Stock performance.
| Return On Equity | -14.81 | ||||
| Return On Asset | -0.21 | ||||
| Profit Margin | (1.29) % | ||||
| Operating Margin | (0.70) % | ||||
| Current Valuation | 273.66 M | ||||
| Shares Outstanding | 42.2 M | ||||
| Price To Earning | 239.57 X | ||||
| Price To Book | 15.73 X | ||||
| Price To Sales | 4.49 X | ||||
| Revenue | 82.71 M | ||||
| Gross Profit | 80.67 M | ||||
| EBITDA | (63.83 M) | ||||
| Net Income | (102.24 M) | ||||
| Cash And Equivalents | 111.74 M | ||||
| Cash Per Share | 4.91 X | ||||
| Total Debt | 100.21 M | ||||
| Debt To Equity | 0.44 % | ||||
| Current Ratio | 7.74 X | ||||
| Book Value Per Share | 0.60 X | ||||
| Cash Flow From Operations | (76.38 M) | ||||
| Earnings Per Share | (3.02) X | ||||
| Market Capitalization | 401.32 M | ||||
| Total Asset | 178.31 M | ||||
| Retained Earnings | (679.35 M) | ||||
| Working Capital | 137.97 M | ||||
About UroGen Pharma Performance
By examining UroGen Pharma's fundamental ratios, stakeholders can obtain critical insights into UroGen Pharma's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that UroGen Pharma is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 254.38 | 241.66 | |
| Return On Tangible Assets | (0.52) | (0.54) | |
| Return On Capital Employed | (0.40) | (0.42) | |
| Return On Assets | (0.52) | (0.54) | |
| Return On Equity | 1.80 | 1.89 |
Things to note about UroGen Pharma performance evaluation
Checking the ongoing alerts about UroGen Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for UroGen Pharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| UroGen Pharma generated a negative expected return over the last 90 days | |
| UroGen Pharma has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 82.71 M. Net Loss for the year was (102.24 M) with profit before overhead, payroll, taxes, and interest of 80.67 M. | |
| UroGen Pharma currently holds about 111.74 M in cash with (76.38 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.91. | |
| UroGen Pharma has a frail financial position based on the latest SEC disclosures | |
| Over 94.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from insidermonkey.com: Is UroGen Pharma Ltd. the Best Small-Cap Growth Stock to Buy Now |
- Analyzing UroGen Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether UroGen Pharma's stock is overvalued or undervalued compared to its peers.
- Examining UroGen Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating UroGen Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of UroGen Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of UroGen Pharma's stock. These opinions can provide insight into UroGen Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in UroGen Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in UroGen Stock, please use our How to Invest in UroGen Pharma guide.You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of UroGen Pharma. If investors know UroGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about UroGen Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.02) | Revenue Per Share | Quarterly Revenue Growth 0.209 | Return On Assets | Return On Equity |
The market value of UroGen Pharma is measured differently than its book value, which is the value of UroGen that is recorded on the company's balance sheet. Investors also form their own opinion of UroGen Pharma's value that differs from its market value or its book value, called intrinsic value, which is UroGen Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because UroGen Pharma's market value can be influenced by many factors that don't directly affect UroGen Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between UroGen Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if UroGen Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, UroGen Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.